OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

医学 指炎 巴斯代人 银屑病性关节炎 内科学 巴斯菲 人口 脊柱炎 乌斯特基努马 末端炎 银屑病 安慰剂 强直性脊柱炎 关节炎 阿达木单抗 胃肠病学 皮肤病科 类风湿性关节炎 替代医学 环境卫生 病理
作者
Arthur Kavanaugh,L. Puig,Alice B. Gottlieb,Christopher T. Ritchlin,Yin You,Y. Wang,Alan M. Mendelsohn,Michael Song,Proton Rahman,Iain B. McInnes
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:74 (Suppl 2): 136.1-136 被引量:4
标识
DOI:10.1136/annrheumdis-2015-eular.3096
摘要

Background

IL-23 may be implicated in spondylitis. A substantial number of pts with spondylitis and peripheral joint involvement were enrolled in PSUMMIT.

Objectives

We evaluated the efficacy of SC UST 45/90 mg in a subgroup of psoriatic arthritis (PsA) pts with physician diagnosed spondylitis and peripheral joint involvement through wk108, from PSUMMIT 1.

Methods

Adult PsA patients (n=615) with active disease (≥5 SJC and ≥5 TJC;CRP≥0.3mg/dL) despite DMARD and/or NSAIDs were randomized to UST45mg, 90mg, or PBO at wks 0, 4, and q12wks. Pts treated with prior anti-TNF agents were excluded. Stable concomitant MTX was permitted but not mandated. At wk16, pts with <5% improvement in TJC & SJC entered blinded early escape (PBO→UST45mg; UST45mg→90mg; 90mg→90mg). PBO pts subsequently crossed over to UST45mg at wk24. Pts received q12w dosing to wk88, with final efficacy evaluation at wk100 and safety assessment at wk108. Pts with spondylitis and peripheral joint involvement as their primary arthritis presentation of PsA also had BASDAI assessments at wks12 and 24.

Results

186 randomized pts (70 PBO, 116 UST combined) had spondylitis with peripheral joint involvement at baseline (30% of overall population); mean baseline characteristics were similar to the overall population (age 45.6yrs, weight 82.8kg, PsA duration 6.3yrs, SJC/TJC 14.3/24.1, HAQ-DI 1.3; BASDAI 6.5, and 26% were HLAB27 positive. Mean baseline scores among pts with dactylitis (n=100), enthesitis (148), and skin disease (147) were 8.3, 5.6, and PASI 14.2, respectively. At wk24, greater proportions of combined UST45/90mg treated pts had improvements in dactylitis/enthesitis measurements, HAQ-DI and ACR20/50/70 responses than PBO (Table). Clinical improvements were generally maintained through wk100. A significantly higher proportion of UST-treated pts achieved BASDAI20/50/70 responses vs. PBO at wk24 (54.1%/27.9%/14.4% vs. 26.2%/13.1%/0.0%). Peripheral structural damage assessed by total vdH-S mean change from baseline also showed improvement in the UST groups vs PBO at wk24. Of the 135 patients with ≥3% BSA involvement and spondylitis with peripheral arthritis at baseline, PASI75 responses were also maintained through wk100. During the PBO-controlled period, the proportion of pts with AEs were comparable between the PBO and combined UST-treated groups (AEs 32.9% vs 24.1%; SAEs 1.4% vs 0.9%; discontinuations due to AEs 2.9% vs 0.9%; serious infections 14.3% vs 7.8%). Through 2yrs, safety observations were consistent with the overall PsA population.

Conclusions

In this post-hoc subgroup analysis, UST significantly improved signs and symptoms, and demonstrated improvements in BASDAI and peripheral radiographic progression compared with PBO through wk24; efficacy was maintained through wk100. UST was well-tolerated and demonstrated a safety profile similar to that observed in the overall PsA study population.

Disclosure of Interest

A. Kavanaugh Grant/research support from: AbbVie, Amgen, Janssen, and UCB., L. Puig Grant/research support from: AbbVie, Amgen, Boehringer, Celgene, Eli Lilly, Janssen, Leo-Pharma, Merck/Schering-Plough, Merck-Serono, Novartis, Pfizer, Sandoz, and VBL., A. Gottlieb Grant/research support from: Amgen, AbbVie, Celgene, Coronado, Eli Lilly, Janssen, Levia, Merck, and Pfizer., Consultant for: AbbVie, Actelion, Akros, Amgen, Astellas, Bristol Myers Squibb, Canfite, Catabasis, Celegene, CSL Behring Biotherapies for Life, Coronado, Dermipsor, Eli Lilly, GlaxoSmithKline, Incyte, Janssen, Karyopharm, Novartis, Novo Nordisk, Pfizer, Sanofi Aventix, UCB, Vertex, and Xenoport., C. Ritchlin Grant/research support from: Amgen, Janssen, and UCB., Consultant for: AbbVie, Amgen, Janssen, Regeneron, Roche, and UCB., Y. You Employee of: Janssen R&D, LLC., Y. Wang Employee of: Janssen R&D, LLC., A. Mendelsohn Employee of: Janssen R&D, LLC., M. Song Employee of: Janssen R&D, LLC., P. Rahman Grant/research support from: AbbVie, Amgen, Janssen, Pfizer, and Novartis., I. McInnes Grant/research support from: AbbVie, BMS, Janssen, Pfizer, Roche, Merck/Schering-Plough, and UCB.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
猫好好完成签到,获得积分10
刚刚
廉不可发布了新的文献求助10
1秒前
Eureka完成签到 ,获得积分10
2秒前
3秒前
蔚蔚蓝天完成签到,获得积分10
3秒前
追寻依风完成签到,获得积分10
3秒前
3秒前
ddsyg126完成签到,获得积分10
3秒前
有魅力的从凝完成签到,获得积分10
3秒前
史呆芬发布了新的文献求助10
3秒前
欣慰的白羊完成签到,获得积分10
4秒前
4秒前
5秒前
煎饼煎饼完成签到,获得积分10
5秒前
淡然觅荷完成签到 ,获得积分10
5秒前
jack1511完成签到,获得积分10
5秒前
庄怀逸完成签到 ,获得积分10
6秒前
单薄的大白菜真实的钥匙完成签到,获得积分10
7秒前
八荒来犬发布了新的文献求助10
7秒前
无私雪碧发布了新的文献求助10
8秒前
呆萌黑猫完成签到,获得积分10
8秒前
9秒前
9秒前
归尘发布了新的文献求助20
9秒前
李泽完成签到,获得积分10
10秒前
冷艳的白莲完成签到,获得积分10
10秒前
风信子完成签到,获得积分10
10秒前
斯文败类应助啊啊啊啊采纳,获得10
10秒前
amberzyc应助阿巴阿巴采纳,获得10
11秒前
ChengYonghui完成签到,获得积分10
12秒前
飞雪完成签到,获得积分10
12秒前
13秒前
13秒前
liutg24完成签到,获得积分10
13秒前
dd发布了新的文献求助10
13秒前
精明尔曼完成签到,获得积分10
13秒前
14秒前
yirenli完成签到,获得积分10
14秒前
14秒前
hesongwen完成签到,获得积分10
15秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
A new approach to the extrapolation of accelerated life test data 1000
徐淮辽南地区新元古代叠层石及生物地层 500
Coking simulation aids on-stream time 450
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4015970
求助须知:如何正确求助?哪些是违规求助? 3555964
关于积分的说明 11319479
捐赠科研通 3289040
什么是DOI,文献DOI怎么找? 1812373
邀请新用户注册赠送积分活动 887882
科研通“疑难数据库(出版商)”最低求助积分说明 812044